Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?

Company Overview - Corcept Therapeutics (CORT) shares increased by 13.6% to close at $69.90, with trading volume significantly higher than usual, contributing to a total gain of 22.1% over the past four weeks [1][2] Drug Development and Market Position - The company submitted a new drug application (NDA) for relacorilant, a selective cortisol modulator aimed at treating endogenous hypercortisolism (Cushing's syndrome), which could expand its market reach beyond the existing treatment Korlym (mifepristone) [2] - Korlym has seen strong demand in recent quarters, indicating a solid market position for Corcept [2] Financial Performance Expectations - Corcept is projected to report quarterly earnings of $0.37 per share, reflecting a year-over-year increase of 32.1%, with revenues expected to reach $195.88 million, up 44.7% from the previous year [3] - The consensus EPS estimate for Corcept has remained stable over the last 30 days, suggesting that the stock's price movement may not sustain without changes in earnings estimate revisions [4] Industry Context - Corcept is classified under the Zacks Medical - Drugs industry, where Aurinia Pharmaceuticals (AUPH) is another player, having closed 1.7% lower at $8, with a return of -9.4% over the past month [4] - Aurinia's consensus EPS estimate has also remained unchanged, projected at $0.05, which represents a significant year-over-year increase of 126.3% [5]